Prevention of systemic toxicity in hyperthermic isolated lung perfusion using radioisotopic leakage monitoring

References

• Rosin RD. (1997). The complications of isolated limb perfusion. Surg Technol Int 6:143–50.
   PubMedGoogle Scholar
• Jakob J, von Rege I, Weiss C, Hohenberger P. (2012). Impact of hyperthermic isolated limb perfusion on tumour oxygenation in soft tissue sarcoma. Int J Hyperthermia 28:591–6
   PubMed Web of Science ®Google Scholar
• Olofsson R, Lindberg E, Karlsson-Parra A, et al. (2013). Melan-A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma. Int J Hyperthermia 29:234–8
   PubMed Web of Science ®Google Scholar
• Creech Jr O, Ryan RF, Krementz ET. (1961). Regional chemotherapy by isolated perfusion in the treatment of melanoma of the extremities. Plast Reconstr Surg Transplant Bull 28:333–46.
   PubMedGoogle Scholar
• Olofsson R, Ny L, Eilard MS, et al. (2014). Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials 15:317.
   PubMed Web of Science ®Google Scholar
• Ratto GB, Toma S, Civalleri D, et al. (1996). Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 112:614–22.
   PubMed Web of Science ®Google Scholar
• Stehlin Jr JS, Clark Jr RL, Dewey WC. (1961). Continuous monitoring of leakage during regional perfusion. Arch Surg 83:943–9.
   PubMedGoogle Scholar
• Lienard D, Ewalenko P, Delmotte JJ, et al. (1992). High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10:52–60
   PubMed Web of Science ®Google Scholar
• Thom AK, Alexander HR, Andrich MP, et al. (1995). Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 13:264–73
   PubMed Web of Science ®Google Scholar
• Hohenberger P, Haier J, Schlag PM. (1997). Rhabdomyolysis and renal function impairment after isolated limb perfusion–comparison between the effects of perfusion with rhTNF alpha and a 'triple-drug' regimen. Eur J Cancer 33:596–601.
   PubMed Web of Science ®Google Scholar
• Eggimann P, Chioléro R, Chassot PG, et al. (1995). Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest 107:1074–82.
   PubMed Web of Science ®Google Scholar
• Zwaveling JH, Maring JK, Clarke FL, et al. (1996). High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. Crit Care Med 24:765–70.
   PubMed Web of Science ®Google Scholar
• Daryanani D, Komdeur R, Ter Veen J, et al. (2001). Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol 8:566–72.
   PubMed Web of Science ®Google Scholar
• Alexander C, Omlor G, Berberich R, et al. (1993). Rapid measurement of blood leakage during regional chemotherapy. Eur J Nucl Med 20:187–91.
   PubMedGoogle Scholar
• Van Ginkel RJ, Limburg PC, Piers DA, et al. (2002). Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 9:355–63.
   PubMed Web of Science ®Google Scholar
• Rastrelli M, Campana LG, Valpione S, et al. (2016). Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: a 24-year single-centre experience. Int J Hyperthermia 32:165–72.
   PubMed Web of Science ®Google Scholar
• Andreou D, Werner M, Pink D, et al. (2016). Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma. Int J Hyperthermia 32:159–64
   PubMed Web of Science ®Google Scholar
• Belgrano V, Ben-Shabat I, Bergh P, et al. (2016). Isolated limb perfusion as a treatment option for rare types of tumours. Int J Hyperthermia 32:595–9.
   PubMed Web of Science ®Google Scholar
• Ben-Shabat I, Belgrano V, Hansson C, et al. (2017). The effect of perfusate buffering on toxicity and response in isolated hepatic perfusion for uveal melanoma liver metastases. Int J Hyperthermia 22:1–17.
   Google Scholar
• Hendriks JM, Grootenboers MJ, Schramel FM, et al. (2004). Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial. Ann Thorac Surg 78:1919–26.
   PubMed Web of Science ®Google Scholar
• Den Hengst WA, Van Putte BP, Hendriks JM, et al. (2010). Long-term survival of a phase I clinical trial of isolated lung perfusion with melphalan for resectable lung metastases. Eur J Cardiothorac Surg 38:621–7.
   PubMed Web of Science ®Google Scholar
• Den Hengst WA, Hendriks JM, Balduyck B, et al. (2014). Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases. J Thorac Oncol 9:1547–53.
   PubMed Web of Science ®Google Scholar
• Pass HI, Mew DJ, Kranda KC, et al. (1996). Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. Ann Thorac Surg 61:1609–17.
   PubMed Web of Science ®Google Scholar
• Pogrebniak HW, Witt CJ, Terrill R, et al. (1994). Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. Ann Thorac Surg 57:1477–83.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, van Ginkel RJ, van der Mark TW, et al. (1997). Effects of hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan on pulmonary function assessments. J Immunother 20:202–7.
   PubMed Web of Science ®Google Scholar
• Kristoffersen US, Straalman K, Schmidt G, et al. (2009). Radiation exposure to surgical staff during hyperthermic isolated limb perfusion with 99mTechnetium labeled red blood cells. Int J Hyperthermia 25:86–9.
   PubMed Web of Science ®Google Scholar
• Sedger LM, McDermott MF. (2014). TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future. Cytokine Growth Factor Rev 25:453–72.
   PubMed Web of Science ®Google Scholar
• Gurrola-Díaz CM, Sánchez-Enriquez S, Oregon-Romero E, et al. (2009). Establishment of a cut-point value of serum TNF-alpha levels in the metabolic syndrome. J Clin Lab Anal 23:51–6.
   PubMed Web of Science ®Google Scholar
• Xiao H, Chen L, Luo G, et al. (2014). Effect of the cytokine levels in serum on osteosarcoma. Tumour Biol 35:1023–8.
   PubMed Web of Science ®Google Scholar
• Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. (2001). Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res 21:1355–8.
   PubMed Web of Science ®Google Scholar
• McCullagh A, Rosenthal M, Wanner A, et al. (2010). The bronchial circulation–worth a closer look: a review of the relationship between the bronchial vasculature and airway inflammation. Pediatr Pulmonol 45:1–13.
   PubMed Web of Science ®Google Scholar
• Zanzonico P, Heller S. (2000). The intraoperative gamma probe: basic principles and choices available. Semin Nucl Med 30:33–48.
   PubMed Web of Science ®Google Scholar
• Wierts R, de Jong JR, Lazarenko SV, et al. (2011). Characteristics of a new system for monitoring the leakage factor during regional hyperthermic isolated limb perfusion. Nucl Med Commun 32:853–62.
   PubMed Web of Science ®Google Scholar